文献速递肝病

抗炎与抗纤维化靶点治疗非酒精性脂肪性肝炎的综合视角

An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH.
PubMed 文献 · J Hepatol · 2023-04-14

本文综述非酒精性脂肪性肝炎(NASH)治疗药物研发面临的挑战,系统梳理抗炎与抗纤维化两大治疗策略的靶点与在研药物,包括核受体激动剂、脂毒性调节剂、基因沉默、激素激动剂、免疫调节及细胞治疗等,并指出疾病异质性是个体化有效药物确定的障碍。

要点

  • NASH治疗策略分为改善代谢紊乱与细胞损伤,或直接靶向炎症和纤维化。
  • 抗炎靶点包括核受体激动剂、脂毒性调节剂、基因变异修饰及肠外炎症信号干预。
  • 抗纤维化策略靶向肝星状细胞活化,晚期纤维化可探索细胞治疗促进修复。

核心结论

  • NASH及其纤维化导致肝硬化和临床结局进展,治疗策略或改善代谢失调与细胞损伤,或直接靶向炎症和纤维化。
  • NASH的疾病驱动通路汇聚引发纤维化,而纤维化是可逆的。
  • 疾病异质性(遗传或驱动因素不同)是确定对所有NASH患者有效药物的障碍,将逐步克服。

研究设计与样本

  • 本文为综述,检索范围原文未报告。

主要发现

  • 减少炎症级联激活的靶点包括核受体激动剂(如resmetirom、lanifibranor、奥贝胆酸)、脂毒性调节剂(如aramchol、乙酰辅酶A羧化酶抑制剂)或基因变异修饰(如PNPLA3基因沉默)。
  • 来自循环、脂肪组织或肠道的肝外炎症信号是激素激动剂(司美格鲁肽、替尔泊肽、FGF19/FGF21类似物)、微生物群或生活方式干预的靶点。
  • 应激信号和肝细胞死亡激活免疫应答,涉及先天免疫(巨噬细胞、先天淋巴细胞群)和适应性免疫(自身侵袭性T细胞)机制。
  • 已开发疗法削弱免疫细胞活化、募集(趋化因子受体抑制剂)和应答(如半乳糖凝集素-3抑制剂、抗血小板药物)。
  • 肝星状细胞活化为产基质肌成纤维细胞可被拮抗可溶性因子(如整合素、细胞因子)、细胞串扰(如与巨噬细胞)及激动核受体信号所抑制。

关键数值与推荐

  • 在晚期纤维化中,采用修复性巨噬细胞或重编程(CAR)T细胞的细胞治疗可能通过肝星状细胞失活或杀伤,或增强基质降解来加速修复。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 疾病异质性(遗传或驱动因素不同)是确定对所有NASH患者有效药物的障碍。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Successful development of treatments for non-alcoholic fatty liver disease and its progressive form, non-alcoholic steatohepatitis (NASH), has been challenging. Because NASH and fibrosis lead to progression towards cirrhosis and clinical outcomes, approaches have either sought to attenuate metabolic dysregulation and cell injury, or directly target the inflammation and fibrosis that ensue. Targets for reducing the activation of inflammatory cascades include nuclear receptor agonists (e.g. resmetirom, lanifibranor, obeticholic acid), modulators of lipotoxicity (e.g. aramchol, acetyl-CoA carboxylase inhibitors) or modification of genetic variants (e.g. PNPLA3 gene silencing). Extrahepatic inflammatory signals from the circulation, adipose tissue or gut are targets of hormonal agonists (semaglutide, tirzepatide, FGF19/FGF21 analogues), microbiota or lifestyle interventions. Stress signals and hepatocyte death activate immune responses, engaging innate (macrophages, innate lymphocyte populations) and adaptive (auto-aggressive T cells) mechanisms. Therapies have also been developed to blunt immune cell activation, recruitment (chemokine receptor inhibitors), and responses (e.g. galectin-3 inhibitors, anti-platelet drugs). The disease-driving pathways of NASH converge to elicit fibrosis, which is reversible. The activation of hepatic stellate cells into matrix-producing myofibroblasts can be inhibited by antagonising soluble factors (e.g. integrins, cytokines), cellular crosstalk (e.g. with macrophages), and agonising nuclear receptor signalling. In advanced fibrosis, cell therapy with restorative macrophages or reprogrammed (CAR) T cells may accelerate repair through hepatic stellate cell deactivation or killing, or by enhancing matrix degradation. Heterogeneity of disease - either due to genetics or divergent disease drivers - is an obstacle to defining effective drugs for all patients with NASH that will be overcome incrementally.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Tacke F, Puengel T, Loomba R, et al. An integrated view of anti-inflammatory and antifibrotic targets for the treatment of NASH. J Hepatol. 2023. PMID: 37061196. doi:10.1016/j.jhep.2023.03.038

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。